ADAR1 Capital Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

ADAR1 Capital Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-3,000	Closed	-$567K	–	310
2026 Q1	$567K	Sell	3,000 -5,000	-63%	-$874K	0.03%	197
2025 Q4	$1.36M	Buy	8,000 +5,500	+220%	+$843K	0.1%	119
2025 Q3	$330K	Sell	2,500 -250	-9%	-$30K	0.03%	160
2025 Q2	$292K	Buy	+2,750	New	+$299K	0.04%	141

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return

ADAR1 Capital Management's JAZZ Position: Q2 2026 in Review

ADAR1 Capital Management sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2026, closing a stake of 3,000 shares — an estimated $567K sold.

ADAR1 Capital Management first reported a position in JAZZ in Q2 2025 and held it in 4 quarters. The position peaked at $1.36M in Q4 2025. 647 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

ADAR1 Capital Management reported no remaining Jazz Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
ADAR1 Capital Management sold 3,000 Jazz Pharmaceuticals shares in Q2 2026, an estimated $567K.
ADAR1 Capital Management first reported a position in Jazz Pharmaceuticals in Q2 2025 and held it in 4 quarters.
ADAR1 Capital Management's Jazz Pharmaceuticals position peaked at $1.36M in Q4 2025.
647 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.